Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Research and Markets
DUBLIN, Ireland, October 8, 2013 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/mb7kb8/eclinical_trial) has announced the addition of the "E-Clinical Trial Technologies - Global Strategic Business Report" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
This report analyzes the worldwide markets for E-Clinical Trial Technologies in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets.
Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
I. Introduction, methodology & product definitions
II. Executive summary
1. Industry overview
2. Technological trends
3. E-clinical trials- a broader spectrum
4. Product/service introductions
5. Recent industry activity
6. Focus on select players
7. Global market perspective
1. The united states
5. Rest of world
IV. Competitive landscape
The report profiles 80 companies including many key and niche players such as:
- Aris Global
- Clinipace Worldwide
- Cmed Technology
- DATATRAK International
- DZS Software Solutions
- Medidata Solutions
- Merge Healthcare
- OmniComm Systems
- Phase Forward
- PAREXEL International Corporation
- Perceptive Informatics
- PharmaPros Corporation
- Prelude Dynamics LLC
- SAS Institute
- Target Health
- Trianz Solutions
For more information, including full table of contents, please visit http://www.researchandmarkets.com/research/mb7kb8/eclinical_trial
©2012 PR Newswire. All Rights Reserved.